Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $324.11 Consensus Price Target from Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS) has received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $324.1111.

KRYS has been the subject of several research analyst reports. Citigroup boosted their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Chardan Capital boosted their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. HC Wainwright restated a “buy” rating and set a $310.00 price objective on shares of Krystal Biotech in a research report on Monday, June 1st. Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 5th. Finally, Wall Street Zen upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a report on Saturday, May 9th.

Insider Buying and Selling at Krystal Biotech

In other news, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP increased its holdings in shares of Krystal Biotech by 7.9% during the first quarter. Seven Fleet Capital Management LP now owns 4,316 shares of the company’s stock worth $1,115,000 after buying an additional 316 shares in the last quarter. Western Wealth Management LLC acquired a new position in shares of Krystal Biotech during the first quarter worth $34,000. Bank of America Corp DE increased its holdings in shares of Krystal Biotech by 36.6% during the first quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock worth $67,330,000 after buying an additional 69,840 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Krystal Biotech by 21.5% during the first quarter. Janus Henderson Group PLC now owns 266,659 shares of the company’s stock worth $68,879,000 after buying an additional 47,219 shares in the last quarter. Finally, Cim LLC acquired a new position in shares of Krystal Biotech during the first quarter worth $3,872,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

Shares of KRYS opened at $317.97 on Wednesday. Krystal Biotech has a one year low of $127.99 and a one year high of $331.49. The company has a market cap of $9.37 billion, a P/E ratio of 42.51 and a beta of 0.53. The firm has a 50 day simple moving average of $288.44 and a two-hundred day simple moving average of $267.89.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The business had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. On average, analysts expect that Krystal Biotech will post 7.83 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.